NASH and Systemic Complications : : From Basic to Clinical Research / / Ronit Shiri-Sverdlov and Sabine Baumgartner.

Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress...

Full description

Saved in:
Bibliographic Details
VerfasserIn:
TeilnehmendeR:
Place / Publishing House:Basel, Switzerland : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022.
Year of Publication:2022
Language:English
Physical Description:1 online resource (232 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02822nam a2200301 i 4500
001 993603572904498
005 20230625131909.0
006 m o d
007 cr |||||||||||
008 230625s2022 sz o 000 0 eng d
035 |a (CKB)5400000000046276 
035 |a (NjHacI)995400000000046276 
035 |a (EXLCZ)995400000000046276 
040 |a NjHacI  |b eng  |e rda  |c NjHacl 
050 4 |a R853.C55  |b .S557 2022 
082 0 4 |a 610.724  |2 23 
100 1 |a Shiri-Sverdlov, Ronit,  |e author. 
245 1 0 |a NASH and Systemic Complications :  |b From Basic to Clinical Research /  |c Ronit Shiri-Sverdlov and Sabine Baumgartner. 
246 |a NASH and Systemic Complications  
264 1 |a Basel, Switzerland :  |b MDPI - Multidisciplinary Digital Publishing Institute,  |c 2022. 
300 |a 1 online resource (232 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 |a Description based on publisher supplied metadata and other sources. 
520 |a Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress to fibrosis and cirrhosis, which may eventually lead to liver failure and death. While we have increased our mechanistic knowledge regarding the pathogenesis of NASH within the last decade, treatment options are still limited and liver biopsies have remained the gold standard for diagnosis. To achieve major clinical breakthroughs for NASH patients, it is not sufficient to use a single animal model, since each model has specific limitations. Furthermore, we should rely more on alternative models such as organ-on-a-chip, which will enable us to explore unknown aspects of disease pathogenesis much faster and serve as clinically relevant surrogates for murine models. Another important direction for the improvement of patient health is to pay more attention to extrahepatic, organ-specific and systemic effects, which are associated with NASH. The articles in this Special Issue include an up-to-date overview of the rapidly developing technologies, novel targets for intervention and insights in the field in NASH. Additionally, these articles describe the major challenges in the field, strategies to overcome them and suggestions for future directions. To improve patient's outcome, clinicians, as well as scientists with biomedical, nutrition, physics and mathematics backgrounds, should join forces. Although challenges remain, the future of the field seems promising as these novel technologies and developments are expected to lead to progress in NASH. 
650 0 |a Clinical trials. 
650 0 |a Biomedical materials. 
776 |z 3-0365-2978-0 
700 1 |a Baumgartner, Sabine,  |e editor. 
906 |a BOOK 
ADM |b 2023-07-06 03:28:48 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338184250004498&Force_direct=true  |Z 5338184250004498  |b Available  |8 5338184250004498